UC Davis Health Begins Trial of Innovative Heart Assist Device
加州大學戴維斯分校健康中心展開創新心臟輔助裝置臨床試驗
更新於: 2026年6月27日 上午03:00
UC Davis Health is at the forefront of medical innovation as one of the first hospitals in the Western United States to participate in the SUPPORT II Pivotal Study.
加州大學戴維斯分校健康中心身為西美國首批參與「SUPPORT II 關鍵性研究」的醫院之一，正處於醫學創新的前沿。
This clinical trial evaluates the Supira System, a groundbreaking, low-profile percutaneous ventricular assist device (pVAD).
此項臨床試驗旨在評估 Supira 系統，這是一種具有突破性、低剖面的經皮心室輔助裝置 (pVAD)。
Unlike traditional, bulkier mechanical supports, the Supira System is designed to be smaller, which helps reduce vascular complications and provides cardiologists with better access during complex heart procedures.
與傳統較為笨重的機械支援設備不同，Supira 系統設計更為小巧，有助於減少血管併發症，並在複雜的心臟手術中為心臟科醫師提供更佳的操作空間。
By using built-in sensors, the device offers real-time monitoring of pressure, allowing for more precise patient care.
透過內建感測器，該裝置能夠對壓力進行即時監測，從而實現更精準的病患照護。
This technology is particularly vital for patients with severe heart disease or those experiencing cardiogenic shock, who require hemodynamic support during life-saving interventions like stenting.
這項技術對於嚴重心臟病患或心源性休克患者尤為重要，因為他們在進行如支架置入等救命手術時，需要血流動力學的支持。
Tai Pham, the UC Davis team is contributing to a larger study involving 385 patients nationwide.
來自此項試驗的數據，將在食藥署 (FDA) 的核准流程中發揮關鍵作用，並有望在未來使此項技術成為全國心血管照護的標準配置。
The ultimate goal is to provide safer, more effective options for high-risk patients who were previously deemed ineligible for surgery.
Data from this trial will play a critical role in the FDA approval process, potentially making this technology standard for cardiovascular care across the country in the future.
